After a postdoctoral fellowship at the National Institute of Health in Bethesda (United States), Harald Hampel became professor of psychiatry and created the Center for Research on Alzheimer’s at the University of Munich before being appointed Professor and President of the unit of psychiatry at Trinity College, Dublin. In 2010 he was appointed Professor and President of Psychiatry at the University of Frankfurt. From 2013 to 2019, he was a professor at Sorbonne University, Department of Neurology, Institute for Memory and Alzheimer’s Disease (Pitié-Salpêtrière Hospital, Paris) and holder of the AXA-Sorbonne University chair. In 2019 he joined the Eisai laboratory in the United States, as Vice-President and Head of Global Medical Affairs, Neurology Business Group.
Within the Institute of Memory and Alzheimer’s Disease (IM2A) at Sorbonne University, the AXA-Sorbonne University chair – funded with 3 million euros – is led by Professor Harald Hampel, an internationally renowned expert. Its objective is to improve the diagnosis of Alzheimer’s disease in order to prevent its effects from the asymptomatic stage, in particular by exploring the trail of biomarkers whose recent development has made it possible to study the disease in a new way and to better assess the effectiveness of therapies.
Here are the main challenges of Professor Harald Hampel’s current research:· Investigate the asymptomatic stage of Alzheimer’s disease· Identify new biomarkers to facilitate early diagnosis· Develop new, simpler and less invasive tests· Anticipate the disease in populations at risk· Allow the testing of personalized treatments administered early. His objective is to develop precision medicine, or 4P medicine (Predictive, Preventive, Personalized and Participatory), for neurodegenerative diseases. This evolution of current medicine towards the medicine of the future is made possible by the recent availability of new tools (IT, Big Data, etc.). Prof. Hampel also chairs the APMI (Alzheimer Precision Medicine Initiative), an international consortium designed to support this approach. Harald Hampel has published over 600 research articles and written 8 books, winning numerous awards for his research focused on brain health and disease, biomarkers and therapeutic discovery in Alzheimer’s disease. He has also received international research grants. He is the principal investigator of research consortia and associate editor of the Alzheimer’s Association journal, Alzheimer’s & Dementia.
Selected publications :
- Biomarqueurs sanguins : sur la voie d’un test de dépistage de la maladie d’Alzheimer (2018) Version anglaise
- Médecine de précision et Alzheimer, pourquoi le sexe des patients doit être pris en compte (2018) Version intégrale, Communiqué de presse version française et version anglaise.
- Une nouvelle combinaison de biomarqueurs pour le diagnostic de la MA Version française et version anglaise (2018)
- Amyloïde et troubles cognitifs : quelle association ? version française et version anglaise (2017)
- La neuro-imagerie génétique, une nouvelle approche pour identifier des marqueurs précoces de la maladie, version française et version anglaise (2017)
- Le retour de l’hypothèse cholinergique dans la maladie d’Alzheimer, version française (2017)
- Une nouvelle donnée dans la prise en charge précoce de la maladie d’Alzheimer, version française et version anglaise (2017)
- BACE1 : un nouveau marqueur sanguin pour prédire la maladie d’Alzheimer ? version française et version anglaise (2017)
- A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling (2017)
- A common challenge in older adults: Classification, overlap, and therapy of depression and dementia (2017)
- Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic (2016)
- The Golden Gate for Detection, Treatment and Prevention of Alzheimer’s Disease (2016)
- La médecine de précision pour combattre Alzheimer (2016), et en version anglaise
- Dementia: The rising global tide of cognitive impairment (2016) : lire l’article en version française ou en version anglaise originale
- « Breakthrough studies confirm brain plaques can help predict Alzheimer’s disease » publié dans JAMA (2015) : lire l’article en Version Anglaise ou Version Française
- « Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease » publié dans le dernier Nature : Genetics ABCA7 in AD (2015)